HGH Fragment 176-191

New to peptides? Start with what are peptides? and how do peptides work?

Overview

HGH Fragment 176-191 is a synthetic peptide corresponding to the last sixteen amino acids of the human growth hormone molecule. It exists because of a specific research finding: growth hormone's effects on fat metabolism appear to be concentrated in the C-terminal region of the molecule, separately from the regions responsible for growth and for its effects on blood sugar.

The original idea

The premise was genuinely elegant. Growth hormone reduces fat mass, but it also promotes tissue growth and causes insulin resistance, which makes it unsuitable as a weight-loss treatment. If the fat-reducing activity could be isolated in a fragment, you would in theory have the benefit without the drawbacks. That was the rationale, and it is why the fragment was investigated at all.

What happened next

This is the part usually left out of the marketing. The fragment concept was developed further into AOD-9604, a stabilized, modified version, which went into human clinical trials as an anti-obesity candidate. In those trials it failed to produce meaningful weight loss beyond placebo. That failure is the single most relevant piece of human evidence available for this whole approach, and it points the wrong way for the claims made about Fragment 176-191.

The fragment is not FDA-approved, has no robust human evidence of its own, and is sold only as a research chemical.

How it works

The proposed mechanism

In laboratory and animal work, the fragment has been reported to stimulate lipolysis — the breakdown of stored triglyceride into free fatty acids — and to inhibit lipogenesis, the formation of new fat. This reproduces a specific action of full growth hormone on adipose tissue.

The proposed signaling involves beta-3 adrenergic receptor pathways in fat tissue rather than the growth hormone receptor itself, which is the mechanistic basis for the claim that it acts on fat without producing growth-promoting or diabetogenic effects. Consistent with this, animal work reported that the fragment did not raise IGF-1 or impair glucose tolerance the way growth hormone does.

Why the mechanism story is not enough

Everything above is established largely in rodent adipose tissue and in obese-mouse models. Species differences in fat metabolism are substantial, and a mechanism demonstrated in a mouse is a hypothesis about humans, not a finding in humans. The AOD-9604 trials effectively tested that hypothesis in people, and the answer was negative.

This is a recurring pattern worth recognizing across research peptides: a plausible, well-documented mechanism in animals is frequently presented as though it were evidence of a human effect. It is not the same thing, and where human trials exist they take precedence over mechanism.

Research & evidence

The preclinical work

Early research identified a lipolytic domain in the C-terminal region of growth hormone and characterized the activity of synthetic fragments from that region. Studies in obese mice reported reduced body weight and increased fat oxidation with the fragment and closely related sequences, without the growth or glucose effects of full growth hormone.

The human evidence, via AOD-9604

AOD-9604 — the fragment's stabilized, further-developed descendant — was taken into human clinical trials for obesity. Despite encouraging early-phase signals, the larger trials did not show meaningful weight loss compared with placebo, and development as an obesity drug was discontinued. AOD-9604 was subsequently repositioned toward other applications and has been marketed in some jurisdictions as a supplement or cosmetic ingredient rather than as a weight-loss drug.

There are no robust human trials of HGH Fragment 176-191 itself. Its case rests entirely on animal data plus the failed human program of its closest relative.

How to weigh this

When a compound's better-developed, better-funded successor fails in controlled human trials, that is strong evidence against the parent compound's claims — not neutral information. The honest summary is that the fat-loss claims made for HGH Fragment 176-191 in fitness marketing are not supported by human evidence, and the most relevant human evidence available points against them.

Safety & legal status

What is known

Human safety data for HGH Fragment 176-191 are essentially absent. The related compound AOD-9604 was reported as reasonably well tolerated in its clinical trials, which offers limited reassurance about a related molecule but does not substitute for data on this one. The absence of documented harm in a compound that has barely been studied is not evidence of safety.

Practical risks

• Product quality. Research-chemical peptides are not manufactured to pharmaceutical standards. Independent testing of this market has repeatedly found products that were mislabeled, underdosed, impure, or contaminated. Sterility is a separate concern for anything injected.
• Unknown long-term effects. No chronic-use data exist in humans at any dose.
• Financial risk. Given that the most relevant human evidence points to no meaningful fat-loss effect, the most likely outcome of purchasing this compound is paying for something that does not work.

Legal and sporting status

HGH Fragment 176-191 is not FDA-approved for any use and is sold labeled for research use only — a category covering laboratory materials, not a license for human consumption. Growth-hormone-related peptides and fragments are prohibited in sport by the World Anti-Doping Agency.

We do not publish dosing information for unapproved compounds. See AOD-9604 for the compound with actual human trial data, and our guide to weight-loss peptides for approved alternatives.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. Peer-reviewed study
2. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. Peer-reviewed study
3. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993. Peer-reviewed study
4. Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000. Peer-reviewed study